Aarti Pharmalabs (NSE:AARTIPHARM) Tariff Resilience Score: 0/10 (As of Jul. 06, 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
57 GF Score
Price ₹706.35
GF Value ₹638.88
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Tariff Resilience Score?

Aarti Pharmalabs has the Tariff Resilience Score of 0, which implies that the company might have .

Aarti Pharmalabs has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aarti Pharmalabs might have .

Aarti Pharmalabs  (NSE:AARTIPHARM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aarti Pharmalabs Tariff Resilience Score Related Terms

NSE:AARTIPHARM
57GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹706.35 is trading 10.6% above its estimated GF Value™ of ₹638.88. GuruFocus considers Aarti Pharmalabs to be Modestly Overvalued.

Key valuation signals for NSE:AARTIPHARM:

  • Tariff Resilience Score: 0
  • GF Value™: ₹638.88 vs. price of ₹706.35 (10.6% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
57GF Score

Get the complete analysis for NSE:AARTIPHARM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹706.35
Price
₹638.88
GF Value